Biogen will stop producing drugs at its Cambridge, Massachusetts plant by year-end, a decision that could lead to up to 285 layoffs.
The company is looking to sublease its bioprocessing operation in Kendall Square, but if another tenant can’t be found, Biogen will shut down the 66,000-square-foot plant.
The plant in Cambridge makes two multiple sclerosis drugs, Avonex and Plegridy, and the hemophilia A treatment Eloctate, in 2,000-liter bioreactors. Production of these drugs will be moved to larger sites in North Carolina and Europe.
Read the Boston Globe article